Loading...

Metsera, Inc.

MTSR•NASDAQ
Healthcare
Biotechnology
$40.47
$0.81(2.06%)

Metsera, Inc. (MTSR) Company Profile & Overview

Explore Metsera, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Metsera, Inc. (MTSR) Company Profile & Overview

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

SectorHealthcare
IndustryBiotechnology
CEOChristopher Whitten Bernard

Contact Information

https://metsera.com
212 784 6595
3 World Trade Center, New York City, NY, 10007

Company Facts

93 Employees
IPO DateJan 31, 2025
CountryUS
Actively Trading

Frequently Asked Questions

;